Naslov
RED BLOOD CELL ANTIBODIES IN PATIENTS UNDERGOING LIVER TRANSPLANTATION: A CROATIAN SINGLE CENTRE ANALYSIS

Autori
Lukić, Martina ; Radovčić, Marko Karlo ; Košuta, Iva ; Kocman, Branislav ; Mrzljak, Anna

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Transplant International / - , 2017, 390-390

Skup
18th Congress of the European Society for Organ Transplantation

Mjesto i datum
Barcelona, Španjolska, 24.09.2017. - 27.09.2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
RED BLOOD CELL ANTIGENS ; LIVER TRANSPLANTATION

Sažetak
Background: Red cell alloimmunization in patients awaiting liver transplantation (LT) complicates blood provision for the procedure and may influence the outcome. Our aim was to analyze red blood cell (RBC) antibodies in adults before and after LT and to objectify the scope of the issue. Method: We retrospectively analyzed RBC antibodies of adult recipients before and after LT, during a period 05/2011- 05/2016, in our center.Results:570 patients were reviewed of whom 72.8% were males. 17 (2.98%) patients had a positive indirect antiglobulin test (IAT) at the time of listing. In 15(2.63%) patients RBC alloantibodies were identified with the commonest from the Rhesus blood group system (66.7%) and the Kell blood group system (26.7%). Less common antibodies were from other blood group systems: Kidd, MNS, Duffy, and Lutheran. Single antibody was found in 10 patients, while the rest had multiple antibodies (range 2–5). Of the remaining two patients, one had warm autoimmune hemolytic anemia and in one positive reaction in IAT were non-specific. RBC antibodies were more common in females (4.5%) than in males (2.4%). Median waiting time on the list was 26 days (range: 0– 2792).One patient developed an additional alloantibody from the MNS blood group system by the time of LT. The follow-up RBC antibody screening, in case of clinical indication was performed in 249 (43.7%) patients, with the median of92 days (range 7– 1692) after LT. Additional 0.8% patients developed new antibodies, both from the Rhesus blood group system. Conclusion: Red cell antibodies prevalence (2.63%) in patients awaiting LT is relatively high when compared to the healthy population (blood donors: 1%females, 0.2% males) in our country. Our results show that care should be taken when administering transfusion treatment to chronic liver disease patients and potential LT recipients. Such treatment should whenever possible, be with Rhesus and Kell typed blood to minimize the chance of alloimmunization

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA